View Future GrowthDarwin 過去の業績過去 基準チェック /06Darwinの収益は年間平均-41.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間17% 55%割合で 減少しています。 Darwinの自己資本利益率は0.5%であり、純利益率は0.9%です。主要情報-41.21%収益成長率-41.21%EPS成長率Biotechs 業界の成長-14.59%収益成長率-55.01%株主資本利益率0.54%ネット・マージン0.88%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026すべての更新を表示Recent updatesお知らせ • 12hDarwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.お知らせ • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.New Risk • May 15New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 7.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.90, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026New Risk • Feb 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 36x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past year.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 56% over the past year.New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$91.3m).Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 33%After last week's 33% share price gain to €7.90, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year.New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€70.2m market cap, or US$82.7m).New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.6m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€87.6m market cap, or US$100.0m).Upcoming Dividend • Jun 23Upcoming dividend of €2.25 per shareEligible shareholders must have bought the stock before 30 June 2025. Payment date: 02 July 2025. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.2%).お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.2m).お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.収支内訳Darwin の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XTRA:7V0 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 2562115031 Dec 24271813031 Dec 2318013031 Dec 222104515031 Dec 211332360質の高い収益: 7V0 非現金収入 のレベルが高いです。利益率の向上: 7V0の現在の純利益率 (0.9%)は、昨年(67.5%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 7V0の収益は過去 5 年間で年間41.2%減少しました。成長の加速: 7V0は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 7V0は過去 1 年間で収益成長率がマイナス ( -97% ) となったため、 Biotechs業界平均 ( 45% ) と比較することが困難です。株主資本利益率高いROE: 7V0の 自己資本利益率 ( 0.5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:55終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Darwin AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cosmin FilkerGBC AGKlaus BreitenbachODDO BHF Corporate & Markets
Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026
お知らせ • 12hDarwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
お知らせ • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.
New Risk • May 15New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 7.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).
Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.90, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.
お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026
New Risk • Feb 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 36x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past year.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a forward P/E ratio of 31x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 56% over the past year.
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$91.3m).
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 33%After last week's 33% share price gain to €7.90, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past year.
New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€70.2m market cap, or US$82.7m).
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.6m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (€87.6m market cap, or US$100.0m).
Upcoming Dividend • Jun 23Upcoming dividend of €2.25 per shareEligible shareholders must have bought the stock before 30 June 2025. Payment date: 02 July 2025. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.2%).
お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.2m).
お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.